<?xml version="1.0" encoding="UTF-8"?>
<p>The incidence of kidney cancer is increasing, with renal cell carcinoma (RCC) now accounting for approximately 85% of adult kidney cancers, about 70% of which are clear cell carcinoma (
 <xref rid="B1" ref-type="bibr">1</xref>). The treatment strategy for advanced RCC is evolving from one using multiple target-kinase inhibitors to one using immunotherapy (
 <xref rid="B2" ref-type="bibr">2</xref>). When successful, immunotherapy treatment significantly prolongs overall survival in advanced RCC (
 <xref rid="B3" ref-type="bibr">3</xref>, 
 <xref rid="B4" ref-type="bibr">4</xref>), but it succeeds in only a minority of patients (
 <xref rid="B4" ref-type="bibr">4</xref>). Many clinical trials using combination immunotherapy for advanced RCC have been conducted (
 <xref rid="B3" ref-type="bibr">3</xref>), but few studies exist using immunotherapy combined with cytokine-induced killer (CIK) cells (
 <xref rid="B4" ref-type="bibr">4</xref>).
</p>
